Join Growin Stock Community!

Oramed pharmaceuticals inc.ORMP.US Overview

US StockHealthcare
(No presentation for ORMP)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ORMP AI Insights

ORMP Overall Performance

ORMP AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ORMP Recent Performance

-1.17%

Oramed pharmaceuticals inc.

0.05%

Avg of Sector

-0.31%

S&P500

ORMP PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ORMP Key Information

ORMP Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ORMP Profile

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Price of ORMP

ORMP FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ORMP Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.10
PE Ratio (TTM)
3.42
Forward PE
-
PS Ratio (TTM)
68.04
PB Ratio
0.67
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
0.65%
Net Margin
2192.60%
Revenue Growth (YoY)
196.74%
Profit Growth (YoY)
-98.07%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.10
PE Ratio (TTM)
3.42
Forward PE
-
PS Ratio (TTM)
68.04
PB Ratio
0.67
Price-to-FCF
-
Gross Margin
0.65%
Net Margin
2192.60%
Revenue Growth (YoY)
196.74%
Profit Growth (YoY)
-98.07%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is ORMP's latest earnings report released?

    The most recent financial report for Oramed pharmaceuticals inc. (ORMP) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ORMP's short-term business performance and financial health. For the latest updates on ORMP's earnings releases, visit this page regularly.

  • Where does ORMP fall in the P/E River chart?

    According to historical valuation range analysis, Oramed pharmaceuticals inc. (ORMP)'s current price-to-earnings (P/E) ratio is 2.18, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How much debt does ORMP have?

    As of the end of the reporting period, Oramed pharmaceuticals inc. (ORMP) had total debt of 860K, with a debt ratio of 0. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ORMP have?

    At the end of the period, Oramed pharmaceuticals inc. (ORMP) held Total Cash and Cash Equivalents of 52.18M, accounting for 0.24 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ORMP's EPS continuing to grow?

    According to the past four quarterly reports, Oramed pharmaceuticals inc. (ORMP)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.16. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ORMP?

    Oramed pharmaceuticals inc. (ORMP)'s Free Cash Flow (FCF) for the period is -1.8M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 74.61% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.